Comparison · NCT03018249-7a538731
Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA vs Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat: Percent of Participants With a Ki67 Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA vs Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat: Percent of Participants With a Ki67 Response. Trial comparisons, record NCT03018249-7a538731. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03018249-7a538731
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.682 | 0.473 | 0.836 | wilson | |
| Risk in group 2 | 0.9 | 0.699 | 0.972 | wilson | |
| Risk difference, group 1 minus group 2 | -0.218 | -0.439 | 0.0354 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.758 | 0.55 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.238 | 0.0429 | 1.32 | log | |
Number needed to treat, for one fewer participant with the outcome on Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA than on Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | 4.58 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24. | 15 | 22 | OG000 |
| Group 2 | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24. | 18 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percent of Participants With a Ki67 Response
- Description
- A response was defined as a decrease in Ki-67 protein expression in tumor from pre- to post-treatment.
- Time frame
- Specimens were collected at initial diagnostic biopsy and at hysterectomy on day 21-24 and analyzed in batch.
- Population
Randomized, treated, evaluable pre and post treatment specimens available. There were 2 participants in each reporting group who withdrew consent prior to treatment; no specimens were submitted for these patients. There was one participant with an inevaluable pre-treatment slide. There were two additional patients with insufficient tumor post-treatment and no slides were submitted; one in each reporting group. There was one additional patient with no specimens submitted in reporting group
Source ClinicalTrials.gov
Trial
- Title
- Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
- NCT number
- NCT03018249
- Phases
- EARLY_PHASE1
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
- Interventions
- Entinostat, Hysterectomy, Laboratory Biomarker Analysis, Medroxyprogesterone Acetate
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2021-06-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03018249?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03018249-7a538731